Connecting Research and Experts with Journalists

• share
• favorite_border

A Rutgers researcher’s new formula with Investigational New Drug (IND) status has successfully alleviated a patient’s long-term severe gastrointestinal (GI) illness associated with post-acute COVID-19 syndrome, or long-haul COVID, in a recent study. The study’s results on the formula developed by Liping Zhao, Ph.D., are now published in an article titled “Nutritional Modulation of Gut Microbiota Alleviates Severe Gastrointestinal Symptoms in a Patient with Post-Acute COVID-19 Syndrome” in mBio, a peer-reviewed journal of the American Society for Microbiology.

• share
• favorite_border

In a landmark genetic study of more than 121,000 people, an international consortium called SCHizophrenia Exome Meta-Analysis (SCHEMA), led by researchers at the Broad Institute of MIT and Harvard, has identified extremely rare protein-disrupting mutations in 10 genes that strongly increase an individual's risk of developing schizophrenia. The Genomic Psychiatry Cohort (GPC) study, based at Rutgers, The State University of New Jersey and led by Drs. Carlos and Michele Pato, is a major contributor to this study and the second, complementary study, led by researchers at Cardiff University on behalf of the Psychiatric Genomics Consortium (PGC).

• share
• favorite_border

Rutgers researcher, Grace Brannigan, has co-authored a study published in The Proceedings of the National Academy of Sciences (PNAS) that centers around the connection between gene mutations in protein sequences and diseases.

• share
• favorite_border

A catalyst that converts waste CO₂ to chemical products. A monoclonal antibody that could revolutionize the detection of tuberculosis. Both innovations were developed at rutgers, The State University of New Jersey, and both have received 2024 Edison Patent Awards.